Targeting BCMA in multiple myeloma with a trifunctional NK cell engager - PubMed
3 days ago
- #NK cell engager
- #multiple myeloma
- #BCMA
- Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, necessitating durable therapies.
- Natural killer (NK) cell engagers (NKCEs) offer potent anti-tumor activity with limited cytokine release, presenting a promising alternative to T cell therapies.
- SAR445514 (SAR'514) is a trifunctional NKCE that activates NK cells by co-engaging NKp46 and FcγRIIIa while targeting B cell maturation antigen (BCMA) on MM cells.
- SAR'514, a monovalent format, was selected for its enhanced antibody-dependent cellular cytotoxicity (ADCC).
- SAR'514 demonstrates potent and selective anti-tumor activity in vitro and in vivo, outperforming other FcγRIIIa-immune cell engagers with minimal cytokine release.
- Ex vivo, SAR'514 efficiently activates NK cells from MM patients and induces cytotoxicity against autologous malignant cells, including those resistant to standard therapies.
- These findings support the further development of SAR'514 as a potential therapy for multiple myeloma.